» Articles » PMID: 27492511

Frequency of Comorbidities in Chronic Obstructive Pulmonary Disease, and Impact on All-cause Mortality: A Population-based Cohort Study

Overview
Journal Respir Med
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2016 Aug 6
PMID 27492511
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In chronic obstructive pulmonary disease (COPD), the role of specific comorbidities on all-cause mortality is of major interest particularly with a database representative of the beneficiaries covered by the French health system. We investigated the frequency and the role of major comorbidities on all-cause mortality in a population-based cohort of COPD patients, and whether this impact was modulated by gender.

Methods: A historical cohort was identified in the French claims data. Patients aged ≥45 years were selected in 2006 from the French national claims data (1/97(th) random sample) by at least one of the following criteria: (a) COPD-related hospitalisations, (b) long-term disease status for COPD, (c) dispensations of bronchodilators. Cardiovascular diseases, diabetes, depression and cancer were defined by specific therapy and/or long-term disease status. The impact of comorbidities on mortality was investigated during a seven-year follow-up period (2007-2013), using Cox models.

Results: In 4,237 patients (mean age 68 years, 55% males, mean annual death-rate 4.9%), cardiovascular diseases, diabetes, depression and cancers were identified in 68.7%, 15.2%, 14.2% and 10.6% of patients, respectively. Associations with mortality were significant for cardiovascular diseases (HR = 1.2, 95%CI = [1.0-1.4]), diabetes (HR = 1.2, 95%CI = [1.0-1.4]), depression (HR = 1.4, 95%CI = [1.2-1.6]) and cancers (HR = 1.6, 95%CI = [1.4-1.9]), with no difference between genders.

Conclusions: In the French population, major comorbidities are common in COPD, particularly cardiovascular diseases that occur in over two thirds of patients. The impact of comorbidities on mortality was not related to their prevalence, with cancer having the largest impact.

Citing Articles

Disproportionately raised risk of adverse outcomes in patients with COPD and comorbid type 2 diabetes or depression: Swedish register-based cohort study.

Smith C, Hasselgren M, Sandelowsky H, Stallberg B, Hiyoshi A, Montgomery S Respir Res. 2025; 26(1):84.

PMID: 40045313 PMC: 11883964. DOI: 10.1186/s12931-025-03160-6.


Do Antidepressants Worsen COPD Outcomes in Depressed Patients with COPD?.

Kaplan A Pulm Ther. 2024; 10(4):411-426.

PMID: 39516453 PMC: 11574234. DOI: 10.1007/s41030-024-00277-9.


Living with COPD and its psychological effects on participating in community-based physical activity in Brazil: a qualitative study. Findings from the Breathe Well group.

Martins S, Adams R, Rodrigues E, Stelmach R, Adab P, Chi C NPJ Prim Care Respir Med. 2024; 34(1):33.

PMID: 39455598 PMC: 11511987. DOI: 10.1038/s41533-024-00386-7.


Dynamic changes in quality of life in older patients with chronic obstructive pulmonary disease: a 7-year follow up.

Yu C, Tsai S, Hung J, Su P, Hsu C, Liao X Health Qual Life Outcomes. 2024; 22(1):76.

PMID: 39256723 PMC: 11389236. DOI: 10.1186/s12955-024-02296-1.


Survival following lung volume reduction procedures: results from the UK Lung Volume Reduction (UKLVR) registry.

Buttery S, Lewis A, Alzetani A, Bolton C, Curtis K, Dodd J BMJ Open Respir Res. 2024; 11(1).

PMID: 38423954 PMC: 10910650. DOI: 10.1136/bmjresp-2023-002092.